VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
37 hedge funds and large institutions have $1.9M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 14 closing their positions.
33,500% more call options, than puts
Call options by funds: $672K | Put options by funds: $2K
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
20% less funds holding
Funds holding: 46 → 37 (-9)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
73% less capital invested
Capital invested by funds: $7.06M → $1.9M (-$5.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$854K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$87.7K |
| 3 |
Renaissance Technologies
New York
|
+$33.5K |
| 4 |
AGM
Alpine Global Management
New York
|
+$30.6K |
| 5 |
HF
HRT Financial
New York
|
+$29.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$131K |
| 2 |
Charles Schwab
San Francisco,
California
|
-$86.8K |
| 3 |
Morgan Stanley
New York
|
-$52.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.9K |
| 5 |
Jane Street
New York
|
-$40.1K |
VBIV Hedge Fund Activity: Q3 2023 in Review
37 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q3 2023, worth a combined $1.9M — down 73% from $7.06M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VBIV and 6 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $854K. The largest seller was Y-Intercept (HK), exiting entirely with an estimated $131K sold.
- 37 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q3 2023, down from 46 in Q2 2023.
- Funds reported $1.9M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q3 2023, down 73% quarter-over-quarter.
- 6 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q3 2023 and 14 closed out, a net change of -8 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q3 2023 was Alyeska Investment Group, an estimated $854K added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q3 2023 was Y-Intercept (HK), an estimated $131K sold.
Based on aggregated 13F filings for Q3 2023.